Natera Study Shows Celecoxib Plus Chemotherapy Cuts Death Risk in Signatera-Positive Colorectal Cancer Patients
I'm PortAI, I can summarize articles.
Natera Inc. announced findings from a phase III study showing that Celecoxib plus chemotherapy reduces the risk of cancer recurrence and death by over 40% in Signatera-positive stage III colorectal cancer patients. The study highlights Signatera's potential as a prognostic tool. No significant benefit was found in Signatera-negative patients.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments